Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tricilest is a triphasic oral contraceptive pill developed by Janssen-Cilag, specifically marketed in Thailand. It consists of a combination of the synthetic estrogen ethinyl estradiol and the progestin norgestimate. As a hormonal combination therapy, it is indicated for the prevention of pregnancy and the treatment of mild to moderate acne vulgaris in women who also require contraception. The mechanism of action involves the suppression of gonadotropins (FSH and LH), which inhibits ovulation, and the modulation of androgen levels. By increasing sex hormone-binding globulin (SHBG) and decreasing free testosterone, Tricilest reduces sebum production, a key factor in the pathogenesis of acne.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tricilest.